The aim of the CLARITY Study is to investigate the effectiveness and safety of ibrutinib used in combination with venetoclax in patients with CLL who are relapsed/refractory. The trial may also give us information about how using both of the drugs together affects the rate of growth, and the lifespan, of leukaemia cells.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
|
Chief Investigator:
|
Professor Peter Hillmen
|
|
Sponsor:
|
University of Birmingham
|
|
Funders:
|
TAP Bloodwise
|
|
Disease Site:
|
Chronic Lymphocytic Leukaemia
|
|
Trial Type:
|
Clinical Trial of an Investigational Medicinial Product
|
|
Status:
|
Open
|
|
UKCRN Study ID: (if applicable)
|
20572
|
|
Open to new sites?
|
Yes
|
|
Recruitment start date:
|
20-May-2016
|
|
Anticipated Recruitment end date
|
20-Nov-2017
|
|
CRCTU Trial Management Team:
|
Haematology
|
|
Trial E-mail Address:
|
CLARITY@trials.bham.ac.uk
|